MarketPulse

psoriasis treatment

2 articles
BenzingaBenzinga··Vandana Singh

J&J and Protagonist Win FDA Approval for Oral Psoriasis Drug, Challenging AbbVie's Market Dominance

FDA approves Icotyde for psoriasis, triggering $50M payment to Protagonist. Market reacts with AbbVie stock falling 5.20% amid competitive pressure.
JNJABBVPTGXFDA approvalplaque psoriasis
BenzingaBenzinga··Vandana Singh

Eli Lilly's Dual-Therapy Approach Demonstrates Enhanced Efficacy in Psoriasis-Obesity Treatment

Eli Lilly's combo therapy of Taltz and Zepbound showed superior results for psoriasis-obesity patients, achieving 27.1% complete skin clearance versus 5.8% for monotherapy.
LLYCSLLYPhase 3b trialZepbound